Recent advancements in diagnosis and treatment of metastatic colorectal cancer to the liver

Surgical Oncology

Volumn 15, Issue 3, 2006, Pages 129-134

  Morris, Katherine T ^a   Song, Tae Jin ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Liver metastases; Metastatic colorectal cancer

Indexed keywords

DEXAMETHASONE; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE FREE INTERVAL; DRUG RESPONSE; HUMAN; LAPAROSCOPY; LIVER METASTASIS; LIVER RESECTION; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DIAGNOSTIC IMAGING; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PATIENT SELECTION; PORTAL VEIN;

EID: 33846900383     PISSN: 09607404     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suronc.2006.10.004     Document Type: Review

References (38)

1. Foster J.H. Survival after liver resection for secondary tumors. American Journal Surgery 135 3 (1978) 389-394
2. Hughes K.S., Simon R., Songhorabodi S., Adson M.A., Ilstrup D.M., Fortner J.G., et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 100 (1986) 278-284
3. Nordlinger B., Guiguet M., Vaillant J.C., Balladur P., Boudjema K., Bachellier P., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77 7 (1996) 1254-1262
4. Iwatsuki S., Esquivel C.O., Gordon R.D., and Starzl T.E. Liver resection for metastatic colorectal cancer. Surgery (1986) 804-810
5. Doci R., Gennari L., Bignami P., Montalto F., Morabita A., and Bozzetti F. One hundred patients with hepatic metastases from colorectal cancer treated by resection: analysis of prognostic determinants. British Journal Surgery 78 (1991) 797-801
6. Fong Y., Sun R.L., Jarnagin W., and Blumgart L.H. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Annals of Surgery 229 6 (1999) 790-799
7. Nordlinger B., Parc R., Delva E., Quilichini M., Hannoun L., and Huguet C. Hepatic resection for colorectal liver metastases. Annals of Surgery 205 (1987) 256-263
8. Scheele J., Stangl R., Altendorf-Hofmann A., and Gall F.P. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110 (1991) 13-29
9. Butler J., Attiyeh F.F., and Daly J.M. Hepatic resection for metastases of the colon and rectum. Surgery, Gynecology and Obstetrics 162 (1986) 109-113
10. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals Of Surgery 230 3 (1999) 309-318
11. Mala T., Bohler G., Mathisen O., Bergan A., and Soreide O. Hepatic resection for colorectal metastases: can preoperative scoring predict patient outcome? World Journal of Surgery 26 11 (2002) 1348-1353
12. Jarnagin W.R., Conlon K., Bodniewicz J., Dougherty E., DeMatteo R.P., Blumgart L.H., et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 91 6 (2001) 1121-1128
13. Strasberg S.M., and Siegal B.A. Survival of patients staged by FDG-PET before resection of hepatic metastases from colorectal cancer. Annals of Surgery 235 2 (2002) 308
14. Schussler-Fiorenza C.M., Mahvi D.M., Niederhuber J., Rikkers L.F., and Weber S.M. Clinical risk score correlates with yield of PET scan in patients with colorectal hepatic metastases. Journal of Gastrointestinal Surgery 8 2 (2004) 150-157
15. Azoulay D., Castaing D., Krissat J., Smail A., Hargreaves G.M., Lemoine A., et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver. Annals of Surgery 232 5 (2000) 665-672
16. Bismuth H., Adam R., Levi F., Farabos C., Waechter F., Castaing D., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Annals of Surgery 224 4 (1996) 509-520
17. Adam R., Delvart V., Pascal G., Valeanu A., Castaing D., Azoulay D., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Annals of Surgery 240 4 (2004) 644-657
18. Kemeny N.E. Emerging Strategies for the Treatment of Metastatic Colorectal Cancer: current approaches for liver-only metastases in colorectal cancer. Community Oncology 3 6 supp 2 (2006) 26-35
19. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. Journal of the American College of Surgeons 200 6 (2005) 845-853
20. Kemeny N., Jarnagin W.R., Paty P., Gonen M., Schwatrtz L., Morse M., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Journal of Clinical Oncology 23 22 (2005) 4888-4896
21. Ensminger W.D., Rosowsky A., Raso V., Levin D.C., Glode M., Come S., et al. A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluorouracil. Cancer Research 38 11 (1978) 3784-3792
22. Hohn D.C., Stagg R.J., Friedman M.A., Hannigan J.F., Rayner A., Ignoffo R.J., et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California oncology group trial. Journal of Clinical Oncology 7 11 (1989) 1646-1654
23. Wagman L.D., Kemeney M.M., Leong L., Terz J.J., Hill L.R., Beatty J.D., et al. A prospective, randomized evaluation of the treatment of colorectal cancer metastatic to the liver. Journal of Clinical Oncology 8 11 (1990) 1885-1893
24. Kemeny N., Daly J., Reichman B., Geller N., Botet J., and Oderman P. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma-a randomized trial. Annals of Internal Medicine 107 4 (1987) 459-465
25. Kemeny N.E., Niedzwiecki D., Hollis D.R., Lenz H.J., Naughton M.J., Weeks J.C., et al. Hepatic arterial infusion (HAI) versus systemic therapy for hepatic metastases from colorectal cancer; a CALGB randomized trial of efficacy, quality of life (QOL), cost effectiveness, and molecular markers. Proceedings of the American Society for Clinical Oncology 22 (2003) 252a (abstract 1010)
26. Paty P., Fong Y., Harris R., Koenigsberg A., Schwartz L., Jarnagin W., et al. Update of phase I studies of hepatic arterial infusion (HAI) of floxuridine (FUDR) and dexamethasone (DEX) plus: systemic oxaliplatin (Oxal) and irinotecan (CPT-11) or systemic oxal and fluorouracil (FU) and leucovorin (LV) for unresectable hepatic metastases from colorectal cancer. Proceedings of the American Society for Clinical Oncology 22 (2003) (abstract 1160)
27. Kemeny N., Jarnagin W., Paty P., Gonen M., Schwartz L., Morse M., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. Journal of Clinical Oncology 23 22 (2005) 4888-4896
28. Kemeny N.E., Jarnagin W., Gonen M., Haviland D., D'Angelica M., Blumgart L., et al. Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and demamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) + leucovorin (LV) after resection of hepatic metastases from colorectal cancer. Journal of Clinical Oncology 23 16S (Pt I of II) (2005) 3579
29. Kemeny N., Jarnagin W., Gonen M., Stockman J., Blumgart L., Sperber D., et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. Journal of Clinical Oncology 21 17 (2003) 3303-3309
30. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 18 16 (2000) 2938-2947
31. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 22 1 (2004) 23-30
32. Kemeny M.M., Adak S., Gray B., Macdonald J.S., Smith T., Lipsitz S., et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy-an intergroup study. Journal of Clinical Oncology 20 6 (2002) 1499-1505
33. Kemeny N., Huang Y., Cohen A.M., Shi W., Conti J.A., Brennan M.F., et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. New England Journal of Medicine 341 27 (1999) 2039-2048
34. Lygidakis N.J., Sgourakis G., Vlachos L., Raptis S., Safioleas M., Boura P., et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepato-Gastroenterology 48 42 (2001) 1685-1691
35. Lorenz M., Muller H.H., Schramm H., Gassel H.J., Rau H.G., Ridwelski K., et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Annals of Surgery 228 6 (1998) 756-762
36. Kemeny N., and Gonen M. Hepatic arterial infusion after liver resection. New England Journal of Medicine 352 (2005) 734-735
37. Alberts S.R., Mahoney M., Donahue J., Roh M., Wagman L., and Bolton J. Safety of systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following resection of colorectal metastases (M-CRC) confined to the liver: a North Central Cancer Treatment Group (NCCTG) phase II intergroup trial. 2004 ASCO Gastointestinal Cancers Symposium. Proceedings of the American Society for Clinical Oncology 22 (2004) 263a (abstract 205)
38. Alberts S.R., Mahoney M.R., Donohue J., Roh M.S., Green E.M., Sargent D.J., et al. Systemic capecitabine and oxaliplatin administered with hepatic arterial infusion (HAI) of floxuridine (FUDR) following complete resection of colorectal metastases (M-CRC) confined to the liver: a North Central Cancer Treatment Group (NCCTG) phase II intergroup trial. Journal of Clinical Oncology 24 18S (2006) 152S